Medicare has seen a sharp increase in prescriptions for the weight loss drug Wegovy since the program expanded coverage to include people with heart disease. The move allows certain Medicare beneficiaries with a history of cardiovascular problems to access the medication for both weight management and heart health. This policy change represents a significant shift in how Medicare approaches obesity treatments with proven cardiovascular benefits.

  • Medicare prescription claims for Wegovy rose dramatically after coverage was expanded for people with heart disease.
  • The policy change allows Medicare Part D plans to cover Wegovy for beneficiaries with a history of heart attack, stroke, or other cardiovascular conditions.
  • The expansion follows clinical trial data showing semaglutide, the active ingredient in Wegovy, can reduce the risk of major adverse cardiovascular events.
  • Experts expect continued growth in Wegovy prescriptions as awareness of the expanded coverage spreads among doctors and patients.

Background on Wegovy and Medicare

Wegovy, a brand name for semaglutide, was originally approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Until recently, Medicare Part D plans generally did not cover drugs prescribed solely for weight loss due to a statutory exclusion. However, the program can cover such medications if they are approved for a different medical use.

In March 2024, the FDA expanded Wegovy’s label to include reducing the risk of major adverse cardiovascular events in adults with overweight or obesity who also have established cardiovascular disease. This approval opened the door for Medicare coverage under Part D for beneficiaries who meet those criteria. According to the original report by News-Medical, prescription claims for Wegovy spiked shortly after the coverage expansion took effect.

Details of the Coverage Expansion

Under the new policy, Medicare Part D plans may cover Wegovy for beneficiaries who have both a body mass index (BMI) of 27 or higher and a history of cardiovascular disease, such as a heart attack or stroke. The coverage is based on the drug’s FDA-approved indication for cardiovascular risk reduction, not solely for weight loss. This distinction allows Medicare to bypass the traditional exclusion for weight loss drugs.

The Centers for Medicare & Medicaid Services (CMS) has not made Wegovy a mandatory Part D drug, meaning coverage decisions are at the discretion of individual plan sponsors. Nonetheless, many plans have chosen to include the medication on their formularies, and the News-Medical analysis shows a steep rise in prescriptions since the expansion was announced.

Reasons Behind the Spike

Several factors have contributed to the surge in Medicare Wegovy prescriptions. First, the expanded label provides a clear medical justification for coverage that aligns with Medicare’s rules. Second, clinical evidence from the SELECT trial demonstrated that semaglutide reduced the risk of heart attack, stroke, and cardiovascular death by 20% in people with overweight or obesity and preexisting cardiovascular disease. This data convinced many physicians to prescribe Wegovy for heart health in addition to weight loss.

Additionally, patient demand has increased as news of the cardiovascular benefits reaches older adults who are at higher risk for heart disease. The News-Medical report highlights that the number of monthly prescription claims for Wegovy among Medicare beneficiaries jumped significantly in the months following the coverage announcement, with no signs of slowing down.

Implications for Patients and the Healthcare System

The coverage expansion may improve access to an effective treatment for millions of Medicare beneficiaries who struggle with obesity and heart disease. However, the high cost of Wegovy, which can exceed $1,300 per month before insurance, remains a barrier. While Medicare coverage reduces out-of-pocket costs for enrolled patients, the overall expense could put pressure on Part D budgets and potentially affect premiums.

Healthcare providers are beginning to incorporate Wegovy into cardiovascular risk management protocols. The News-Medical analysis suggests that the prescription trend is likely to continue as more clinicians become aware of the coverage change and the supporting evidence. Long-term, this shift may lead to broader Medicare coverage of other weight loss drugs that demonstrate similar cardiovascular benefits.

Frequently Asked Questions

Does Medicare cover Wegovy for weight loss only?

No. Medicare does not cover drugs prescribed solely for weight loss due to a statutory exclusion. However, because Wegovy is now FDA-approved to reduce cardiovascular risk in certain patients, Medicare Part D plans may cover it for beneficiaries who have both obesity or overweight and established heart disease. The coverage is tied to the cardiovascular indication, not weight loss alone.

How quickly did prescriptions increase after the coverage expansion?

According to the original report by News-Medical, prescription claims for Wegovy among Medicare beneficiaries rose sharply within a short period after the policy change took effect. The spike was substantial enough to be noted in prescription data analytics, though exact percentages were not provided in the summary.

Will other weight loss drugs see similar Medicare coverage expansions?

Possibly. Medicare coverage for weight loss drugs is only possible if they receive FDA approval for a separate medical condition that is covered by Part D. Other medications in the GLP-1 class, such as Mounjaro and Zepbound, are also being studied for cardiovascular benefits. If they gain FDA approval for heart health indications, they may also become eligible for Medicare coverage.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.